A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.

Trial Details

NCT ID
NCT05512208
Phase
PHASE2
Sponsor
University of Oklahoma
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Avutometinib (VS-6766) + defactinib
Locations (sample)
  • Orlando, Florida, United States|28.53834,-81.37924
  • New Orleans, Louisiana, United States|29.95465,-90.07507
  • Albuquerque, New Mexico, United States|35.08449,-106.65114
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Female subjects ≥ 18 years of age.
  • Histologically proven gynecological cancers (endometrioid, MOC, HGSOC and solid gynecological cancers) with mutated RAS, BRAF (type I, II, and/or I…
  • Mutational status will be taken from the previous next-gen sequencing (NGS) or molecular testing results and reviewed by the Principal Investigator…
  • Adequate pathology material (as defined in the lab manual) must be available prior to treatment assignment to be used for confirmation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →